Efficacy and safety of BI 1358894 in patients with borderline personality disorder: results of a phase 2 randomized, placebo-controlled, parallel group dose-ranging trial

Objective: To provide proof-of-concept (PoC), dose-range finding, and safety data for BI 1358894, a TRPC4/5 ion channel inhibitor, in patients with borderline personality disorder (BPD).

Bibliographic Details

Main Authors:	Dwyer, Jennifer Holt (Author) , Schmahl, Christian (Author) , Makinodan, Manabu (Author) , Fineberg, Sarah K. (Author) , Sommer, Stephanie (Author) , Wruck, Jan (Author) , Jelaska, Ante (Author) , Adeniji, Abidemi (Author) , Goodman, Marianne (Author)
Format:	Article (Journal)
Language:	English
Published:	January 13, 2025
In:	The journal of clinical psychiatry Year: 2025, Volume: 86, Issue: 1, Pages: 1-28
ISSN:	1555-2101
DOI:	10.4088/jcp.24m15523
Online Access:	Verlag, kostenfrei, Volltext: https://doi.org/10.4088/jcp.24m15523 Verlag, kostenfrei, Volltext: https://www.psychiatrist.com/jcp/efficacy-safety-bi-1358894-borderline-personality-disorder-phase-2-trial/
Author Notes:	Jennifer B. Dwyer, MD, PhD; Christian Schmahl, MD; Manabu Makinodan, MD, PhD; Sarah K. Fineberg, MD, PhD; Stephanie Sommer, PhD; Jan Wruck, MS; Ante Jelaska, MD; Abidemi Adeniji, PhD; and Marianne Goodman, MD